Skip to content

Breast and Cervical Cancer Educational Intervention for Latinas in Western New York

Investigating a Breast and Cervical Cancer Intervention for Latinas in Western New York

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01760850
Enrollment
959
Registered
2013-01-04
Start date
2007-06-30
Completion date
2015-04-30
Last updated
2022-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cervical Cancer

Brief summary

This pilot clinical trial studies a breast and cervical cancer educational intervention for Latinas in Western New York. An outreach program may help minority cancer patients overcome problems that keep them from receiving cancer screening.

Detailed description

PRIMARY OBJECTIVES: I. Investigate the extent of linguistic and cultural tailoring necessary to adapt Esperanza y Vida outreach programs for Hispanics in Western New York. II. Evaluate the effectiveness of the Esperanza y Vida program intervention to increase breast and cervical cancer knowledge and screening behaviors in Hispanic participants compared to a control health education program on diabetes. III. Determine the factors associated with and/or predictive of screening of Hispanics in Western New York (WNY) as compared to New York City (NYC) and Arkansas to describe how the intervention impacts barriers and motivations for screening in diverse Hispanic populations. OUTLINE: Key informant interviews with local gatekeepers of Hispanic culture groups in WNY and focus groups with Hispanic cancer survivors with screened and unscreened participants are conducted during the first phase of research. Participants are then randomized to 1 of 2 arms. ARM I: Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer. ARM II: Participants engage in an educational information session for diabetes. After completion of study treatment, participants are followed up at 2 and 8 months.

Interventions

OTHEReducational intervention

Engage in the Esperanza y Vida educational information session for breast and cervical cancer

OTHERquestionnaire administration

Ancillary studies

Sponsors

Roswell Park Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men and women who are generally healthy, ambulatory, and able to participate in social events in their communities * No women, men, or children of any ethnic or social background are ever excluded from the educational programs, although recruitment will focus on Hispanic/Latinos * Children may be present with parents, but will not be included in any research activities, unless they are emancipated minors (under 18 and married) * Men are included in all of the research activities, but will not be included in the follow-up telephone surveys to assess breast and cervical screening as they do not obtain screening Pap smears, clinical breast exams, or mammograms; men may be asked about their intent to assist women in obtaining screening

Design outcomes

Primary

MeasureTime frameDescription
Screening rates2 monthsIntervention-group screening rates will be compared for evidence of increase over control-group screening rates using the Chi-square test, conducted as a one-sided test at alpha = 0.05. And in stratified analysis, screening rates across both states will be compared for evidence of an overall increase with intervention using the Cochran-mantel-Haenszel (CMH) test, conducted as a one-sided test at alpha = 0.05.
Knowledge acquisition2 monthsKnowledge acquisition within the intervention group will be assessed using the 1-sided paired t-test at alpha = 0.05, while differences in knowledge acquisition between groups will be assessed using Analysis of Covariance (ANCOVA).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026